3415A 3 Ave NW, Calgary, Alberta, T2N 0M4, Canada

Patient Name: Patient, Name
Specimen ID (SID): 25-001-0000
External SID: 123456789
Specimen Type: Plasma
DOB: 01-Jan-2000
Doctor: Dr. Doctor
Date/Time Collected: 01-Jan-2025 / 00:00
PHN: AB 0000000
Report Date: 12-Mar-2025
Specimen Source: MitogenDx
Reason for Testing: Paraneoplastic syndrome
Relevant Medications: -

Soluble Cytokine Receptor Panel

Laboratory Developed Test (LDT)

Analyte	Results (pg/ml)		Reference Interval†
sCD30	< 122		0 - 208
sEGFR	27754		17273 - 55289
sgp130	42256		8649 - 54314
sIL-1RI	58.2		6.2 - 71.2
sIL-1RII	2728		1032 - 10251
sIL-2Rα	4911	**HIGH**	83 - 1815
sIL-4R	< 244		0 - 778
sIL-6R	4401		3356 - 12040
sRAGE	< 7.5		0 - 20.9
sTNFRI	2739	**HIGH**	154 - 1829
sTNFRII	10639	**HIGH**	1578 - 8190
sVEGFR1	< 152		0 - 1028
sVEGFR2	9367		4570 - 21298
sVEGFR3	316		0 - 912

Sample Comments:

-

Results Interpretation:

Possible abnormalities have been detected in TNF family signaling (sTNFRI, sTNFRII) and T cell activation (sIL-2Rα).

Disclaimer:

The interpretation of these test results should be correlated with clinical findings and other diagnostic tests. Biomarker levels can vary due to many biological, physiological, and diurnal factors; their clinical significance must be assessed by a qualified healthcare professional. This information is not intended to be used as the sole basis for diagnosis or treatment decisions.

Reviewed by: DP
Eve Technologies Corporation is a CLIA certified High Complexity International Laboratory
† Reference intervals estimated by data-mining ≥1500 PLASMA samples drawn from both healthy and pathological subjects.